Clinical trials: Peyronies Disease
Peyronie's Disease
A Study of AA4500 in Men With Peyronie's Disease
This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug…
- Trial name
- NCT01243411
- Testing
- AA4500
- Where
- 39 sites in United States, Denmark and 7 more
- Volunteers
- 348 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease
This study is a Phase 2, open-label study to assess the pharmacokinetics (PK) and safety of AA4500 0.58 mg in men with Peyronie's disease.
- Trial name
- NCT01430169
- Testing
- AA4500
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug…
- Trial name
- NCT01685437
- Testing
- AA4500
- Volunteers
- 189 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD
Prospective, open labeled, non-randomized, study to be conducted at a single center. Ten subjects will undergo an injection of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs) into the penis for the treatment of…
- Trial name
- PMD-MSC-PD-01 (NCT02395029)
- Testing
- Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Melissa Marchand
Peyronie's Disease
Peyronie's Disease Treatment Protocol
Treatment of Peyronie's disease remains difficult. The purpose of this study is to test the safety and efficacy of a new compound to treat this disease.
- Trial name
- NCT02072018
- Testing
- H-100
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Hybrid Medical